TME Pharma N.V. (ALTME) — Cash Flow-to-Debt Ratio
TME Pharma N.V. (ALTME) has a Cash Flow-to-Debt Ratio of -0.15x as of December 2025, meaning its operating cash flow of €-557.00K could theoretically repay 0% of its total liabilities (€3.72 Million) in one year. See TME Pharma N.V. (ALTME) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
TME Pharma N.V. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for TME Pharma N.V. across 12 annual periods. For the full cash flow conversion analysis, see ALTME operating cash flow.
Annual Cash Flow-to-Debt Ratio for TME Pharma N.V. (2014–2025)
Year-by-year debt coverage analysis for TME Pharma N.V.. Check TME Pharma N.V. (ALTME) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.92x | €-3.42 Million | €3.72 Million | ▲ +64.5% |
| 2024 | -2.59x | €-4.63 Million | €1.79 Million | ▼ -27.8% |
| 2023 | -2.02x | €-5.63 Million | €2.79 Million | ▼ -8.5% |
| 2022 | -1.86x | €-12.14 Million | €6.51 Million | ▲ +20.7% |
| 2021 | -2.35x | €-12.38 Million | €5.27 Million | ▼ -33.0% |
| 2020 | -1.77x | €-5.22 Million | €2.96 Million | ▼ -47.9% |
| 2019 | -1.20x | €-4.29 Million | €3.59 Million | ▼ -112.9% |
| 2018 | -0.56x | €-4.00 Million | €7.12 Million | ▲ +35.8% |
| 2017 | -0.87x | €-4.24 Million | €4.85 Million | ▲ +48.0% |
| 2016 | -1.68x | €-8.99 Million | €5.35 Million | ▼ -62.9% |
| 2015 | -1.03x | €-13.48 Million | €13.07 Million | ▲ +22.7% |
| 2014 | -1.33x | €-12.46 Million | €9.33 Million | — |